INR deviations in hemodialyzed patients under low dose oral anticoagulant therapy

International Journal of Artificial Organs

Volumn 32, Issue 10, 2009, Pages 752-755

  Gompou, Athina ^a   Griveas, Ioannis ^a   Kyritsis, Ilias ^a   Agroyannis, Ioannis ^a   Tsakoniatis, Manonis ^a   Agroyannis, Basilis ^a  

^a Nefroiatriki Renal Unit   (Greece)

Author keywords

Hemodialysis; Oral anticoagulation; Uremia

Indexed keywords

ANTI-COAGULATION; ANTICOAGULATION THERAPY; BLEEDINGS; HAEMODIALYSIS; INTERNATIONAL NORMALIZED RATIOS; LOW DOSE; ORAL ANTICOAGULANT THERAPIES; ORAL ANTICOAGULATION; UREMIA; UREMIC PATIENTS;

DRUG DOSAGE;

ACENOCOUMAROL;

ABSENCE OF SIDE EFFECTS; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL ARTICLE; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ELDERLY CARE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MALE; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; THROMBOSIS PREVENTION; UREMIA;

EID: 71449113744     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880903201007     Document Type: Article

References (12)

1. Nast SL, Tierney MJ, Mcllwain R. Anticoagulation management in remote primary care. Can Fam Physician 2005; 51: 384-5.
2. Van Walraven C, Jennings A, Oaken N, Fergusson D, Foster A. Effect of study setting on anticoagulation control. A systematic review and metaregression. Chest 2006; 129: 1155-66.
3. Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 2007; 63: 1135-41.
4. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006; 4: 1853-63.
5. Varquez E, Sanchez-Perales C, Garcia-Cortes MJ, et al. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants? Int J Cardiol 2003; 87: 135-9.
6. Ziai F, Benesch T, Kodrask, Neumanni, Dimopoulos-Xicki J, Haas M. The effect of oral anticoagulation on clotting during hemodialysis. Kidney Int 2005; 68: 862-6.
7. Schmidt-Lucke C, Paar WD, Stellbrink C, et al. Quality of anticoagularion with unfractionated heparin plus phenprocoumon for the prevention thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis fom the anticoagulation in cardioversion using Enoxaparin (ACE) trial. Thromb Res 2007; 119: 27-37.
8. Rohde LE, de Assis MC, Rabelo ER. Dietary vitamin K intake and anticoagulation in elderly patients. Curr Opin Clin Nutr Metab Care 2007; 10: 1-5.
9. Hentrich DP, Fritschi J, Muller DR, Wuillemin WA. INR comparison between the Coagu ChekRS and a standard laboratory method among patients with self-management of oral anticoagulation. Thromb Res 2007; 119: 489-95.
10. Wright JR, Kalza PA. Editorial comment: ought dialysis patients with atrial fibrillation be treated with anticoagulants? Int J Cardiol 2003; 87: 139-41.
11. Cranenburg EC, Schurgers LJ, Vermeer. Vitamin K. The coagulation vitamin that became omnipotent. Thromb Haemost 2007; 98: 120-5.
12. Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007; 109: 2419-23.